5 JAN 2017
To celebrate ETC's 10th year anniversary and D3's 5th year anniversary, a symposium titled "Biomedical R&D in Singapore - What Next?" will be held on 9 March 2017. This symposium aims to explore key issues that will guide how research enterprises, like ETC and D3, position themselves for the future of biomedical research will be held on 9 March 2017. Full information of the symposium is available in the booklet.
9 MAR 2017
Singapore's second cancer drug, ETC-206 has entered clinical trials. ETC-206 aims to treat blood cancers, and could reduce or eliminate the potential side effects of cancer treatments when the drug is administered to a patient.
ETC-206 was discovered and developed through a collaboration between A*STAR's Experimental Therapeutics Centre (ETC), the Drug Discovery and Development (D3) unit and Duke-NUS Medical School. The Singapore Clinical Research Institute (SCRI), together with D3, is coordinating the clinical trials.
25 APR 2017
Singapore's concerted push into health and biomedical sciences (HBMS) started almost 20 years ago. Two publicly-funded cancer drugs, ETC-159 and ETC-206, have advanced into first-in-man trials in 2015 and 2016 respectively. The progress in Singapore's HBMS ecosystem would not have been possible without the dedication and concerted efforts of ETC and D3 researchers, as well as clinical, academic and industry partners such as ASLAN and Atreca.